-
Benzinga's Bulls & Bears Of The Week: Fitbit, GE, Intel, Target, Walmart And More
Monday, March 5, 2018 - 8:33am | 783Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included a leading semiconductor maker and oilfield services giants. Bearish calls featured a wearable device maker and the world's largest retailer. Volatility was turned up again last...
-
Benzinga's Bulls & Bears For The Past Week: Apple, Tesla, Twitter And More
Sunday, August 6, 2017 - 3:50pm | 643Benzinga has featured a look at many investor favorite stocks over the past week. Bullish calls included a look at the iPhone maker and at a top biotech. Bearish calls featured the leading electric vehicle maker and the president's favorite social media platform. The calendar page has...
-
The Celgene Story Is Bigger Than Revlimid Now; Argus Upgrades
Monday, July 31, 2017 - 12:35pm | 355Argus upgraded Celgene Corporation (NASDAQ: CELG) Monday on the strength of a diversified drug portfolio and a “robust development pipeline” that’s expected to result in several drugs going under regulatory review later this year. The biopharma company saw strong sales of its...
-
Has Celgene Become Vulnerable To 'Revenue Concentration Risk'?
Friday, May 5, 2017 - 8:46am | 297Argus' David Toung downgraded shares of Celgene Corporation (NASDAQ: CELG) from Buy to Hold after fully digesting the company's first-quarter earnings report. Stay Critical, Investors According to Toung, investors have reason to be "concerned" over the company's revenue concentration from Revlimid...
-
New Lawsuit Alleges Celgene Schemed Charities 'To Gain Billions' Of Dollars
Monday, August 1, 2016 - 10:25am | 314Celgene Corporation (NASDAQ: CELG) is the target of a lawsuit, according to a report by Bloomberg, in which the company is alleged to have donated hundreds of millions of dollars to various charities, as "part of a core business scheme to gain billions" of dollars from taxpayers. The allegations...
-
Short-Sellers Shy Away From These 2 Biotechs This Settlement Period
Thursday, July 28, 2016 - 10:03am | 481Short investor interest in a number of biotech stocks dwindled the first two weeks of July, with two stocks leading the trend with share prices for each growing modestly. Biotechnology is one of those segments that has had a rough go so far this year. And yet, short-selling interest in many of...
-
Barron's Picks And Pans: Celgene, Square, Delphi Automotive And More
Sunday, June 19, 2016 - 10:50am | 632Featured stories this weekend in Barron's ponder the prospects for a leading biotech and an unprofitable payment processor. The prospects for a U.K. auto parts supplier are also examined. Other articles offers a look at who wins if Brexit loses and the 100 best hedge funds. "...
-
Biogen And Gilead Sciences Buck Biotech Short Interest Trend
Sunday, June 12, 2016 - 2:35pm | 588Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of both of these stocks rose sharply during the two-week period. Short sellers shied away from many of the...
-
Short Interest Surges In Illumina And Vertex Pharmaceuticals
Friday, May 13, 2016 - 1:26pm | 550Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of one of those two stocks slumped more than 22 percent during the period. Short sellers shied away from many of...
-
Short Sellers Dump Amgen And Baxalta
Friday, May 13, 2016 - 8:56am | 539Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out as leaders of that trend in those two weeks. Shares of one of those two stocks rose while the other slumped during the period. Short sellers moved on only a few of the leading...
-
Short Sellers Dump Vertex, Load Up On Baxalta
Thursday, April 28, 2016 - 8:34am | 588Short interest in many leading biotech stocks declined in the most recent period. Bucking that trend is a biotech company that soon will be acquired by an overseas peer. Short sellers retreated most sharply from a biotech that some analysts now see as a value stock. Between the March 31 and April...
-
Big Biotech In The Earnings Spotlight
Tuesday, April 26, 2016 - 8:08am | 735The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...
-
Amgen, Celgene Buck Short Interest Trend In Biotech Stocks
Thursday, February 11, 2016 - 8:49am | 583Short interest in many of the leading biotech stocks shrank in the most recent period. However, two of the largest biotech companies bucked that trend in late January. Credit Suisse was bullish on both of them during the short interest period. While short sellers shied away from many...
-
Barron's: Here Comes $20 Oil
Sunday, February 7, 2016 - 12:12pm | 644The cover story in this weekend's Barron's makes a case that the price of oil will bottom at $20 a barrel. Why a recovery in oil means a recovery in stocks is also discussed. Other featured articles focus on mutual funds, master limited partnerships and biotech companies. Oil could fall as low as...
-
Barron's Picks And Pans: Kinder Morgan, Gilead Sciences And More
Sunday, February 7, 2016 - 11:49am | 644Featured stories in this weekend's Barron's offer a look at the prospects for MLPS, leading biotechs, small banks and more. The cover story makes a case for the price of oil to bottom at $20 a barrel. Also, check out a special report on the best mutual fund families. "MLPs: The Worst Isn't Over"...